Zivo Bioscience, Inc. income statement ZIVO

Annual Quarterly

In fiscal 2024, which ended Dec 31, 2024, Zivo Bioscience, Inc. reported revenue of $157,220, up 468.6% from the year before. It recorded a net loss of $13.4 million. The operating loss came to $13.4 million, an operating margin of -8498.9%. Diluted earnings per share were -$4.23. Over the twelve months ended Sep 30, 2025, revenue was $209,025 and the net loss was $8.5 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Sep 30, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2016 Dec 31, 2016	FY 2015 Dec 31, 2015	FY 2014 Dec 31, 2014
Revenue	0 +164.5%	0 +468.6%	0	0	0 -100.0%	0	0	—	0	0	0
Cost of revenue	0 +169.8%	0 +575.0%	0	—	—	—	—	—	—	—	—
Gross profit	0 +153.8%	0 +321.6%	0	—	—	—	—	—	—	—	—
Research and development	4 +15.4%	3 +127.7%	1 -38.5%	2 +14.9%	2 -48.1%	4 +62.8%	2 -18.0%	3	1 -23.6%	1 -47.6%	2 +93.6%
Selling, general and administrative	5 -54.0%	10 +74.2%	6 -9.2%	6 -3.0%	7 +38.9%	5 +18.3%	4 +201.2%	1	1 -13.6%	1 -22.0%	1 +3.7%
Operating expenses	9 -37.7%	13 +84.4%	7	—	—	—	—	—	—	—	—
Operating income	-8 +38.1%	-13 -84.0%	-7 +16.8%	-9 -1.0%	-9 -1.0%	-9 -2.4%	-8 -36.2%	-6	-3 -14.2%	-3 +40.7%	-5 -65.7%
Net income	-8 +38.0%	-13 -72.1%	-8 +11.1%	-9 +0.1%	-9 +3.8%	-9 +20.9%	-12 +21.4%	-15	-6 -4.7%	-6 -950.3%	1 +106.7%
Diluted EPS	—	-4.23	—	—	—	—	—	—	—	—	—
Weighted average shares, basic	—	—	—	—	—	—	—	—	—	—	125
Weighted average shares, diluted	—	3	—	—	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	—	—	—	0	0	0	0	—	0	—
EBITDA	—	—	—	—	-9 -1.0%	-9 -2.4%	-8 -36.2%	-6	—	-3	—
Interest coverage	—	—	-305.26x	-655.60x	-193.50x	—	—	—	—	—	-9.99x
Margins
Gross margin	31.68%	31.14%	41.99%	—	—	—	—	—	—	—	—
Operating margin	-4,045.65%	-8,498.85%	-26,267.67%	—	—	-42,778.38%	—	—	—	—	—
Profit margin	-4,059.73%	-8,513.44%	-28,127.25%	—	—	-45,528.64%	—	—	—	—	—
EBITDA margin	—	—	—	—	—	-42,778.38%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ZIVO (OTC)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Bloomfield Hills, MI
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1101026
Former names: HEALTH ENHANCEMENT PRODUCTS INC (until Oct 16, 2014); WESTERN GLORY HOLE INC (until Jan 26, 2004)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.